The deputy general manager of a pharmaceutical company with an annual salary of 600,000 yuan resigned!

【Pharmaceutical Network Industry News】On September 24, Wellcome Pharmaceutical issued an announcement that the company's board of directors received a written resignation report submitted by Mr.
Lie Jianle, deputy general manager of the company, on September 22, 2022, and Mr.
Lie Jianle applied to resign as deputy general manager of the company for personal reasons (the original term of office was until May 16, 2024).

Upon resignation from the above positions, Mr.
Lie will no longer hold any position in the
Company.

In accordance with the Company Law, the Articles of Association of the Company and other relevant provisions, Mr.
Lie Jianle's resignation as deputy general manager of the company shall take effect
from the date on which his resignation report is delivered to the board of directors.

As at the date of this announcement, Mr.
Lie Jianle indirectly holds 592,000 shares of the Company through Lishui Shunze Investment Management Partnership (Limited Partnership), and Mr.
Lie Jianle's spouse or affiliates do not hold shares in the
Company.

Mr.
Lie Jianle and his spouse or related persons have no commitments that should be fulfilled but have not been fulfilled
.

At the same time, the company held the ninth meeting of the third board of directors on September 23, 2022, and deliberated and passed the "Proposal on the Appointment of the Deputy General Manager of the Company"
.

After the nomination of the company's manager and the review of the nomination committee of the board of directors, the board of directors of the company agreed to appoint Mr.
Zhang Zhangqi as the deputy general manager of the company, and the term of office is from the date of deliberation and approval of the board of directors to the expiration of the term of the third board of directors
.

According to his resume, the departing deputy general manager Lie Jianle served as the deputy general manager
of Wellcome Pharmaceutical since March 2015.

In 2021, its annual salary in Wellcome Pharmaceutical reached 600,000 yuan, and in 2020, its annual salary was 483,000 yuan
.

Mr.
Zhang Zhangqi, who is reinstated as a post-80s generation, has served as the investment manager of Wellcome Pharmaceutical, the deputy manager of the OTC Department, the head of the OTC Department, the manager of the OTC Department, the deputy general manager of the OTC Business Department, and since January 2018, he has served as the general manager
of the OTC Division of Wellcome Pharmaceutical.

As of the date of this announcement, Mr.
Zhang Zhangqi indirectly holds 197,000 shares of the Company through Lishui Shunze Investment Management Partnership (Limited Partnership), which has no relationship with the controlling shareholder and actual controller of the Company, has no relationship with other shareholders holding more than 5% of the Company's shares, other directors, supervisors and senior management personnel of the Company, and has not been punished by the China Securities Regulatory Commission and other relevant departments or punished
by the stock exchange.

According to the data, Wellcome Pharmaceutical is a comprehensive high-tech pharmaceutical enterprise integrating drug research and development, production and sales, the main business is the research and development, production and sales of modern Chinese medicine and Western medicine, in addition to the pharmaceutical industry, the company also operates retail chains of pharmaceutical commercial products and other circulation business as a supplement
to the main business.

It is reported that the company has made small achievements in the field of traditional Chinese medicine innovation, such as the Samdan Tong brain drop pills and Huangjia soft liver granules in the research project, which are all 1.
1 class Chinese medicine innovative drugs, and the power of medicine and health field
.

From the perspective of the capital market, the traditional Chinese medicine industry has risen to a national strategic height, favorable policies have been continuously introduced, and the industry expects that Wellcome Pharmaceutical can enjoy the industry dividends
.

"According to the company's current R&D investment and layout, if breakthroughs are made in the field of traditional Chinese medicine innovation and the big health industry chain in the future, the company's profitability can be greatly improved
.
"
The 2022 interim report shows that in the first half of the year, the company achieved operating income of 296 million yuan, a year-on-year decrease of 10.
91%; Net profit attributable to shareholders of listed companies was 56.
9857 million yuan, a decrease of 10.
64% year-on-year; Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was RMB43.
8597 million, a year-on-year decrease of 18.
43%; Basic earnings per share were RMB0.
394
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.